The purpose of this study was to evaluate the ability of a modified live (ML) canine parvovirus (CPV) type 2b vaccine, to elicit active immunization in pups with maternally derived antibodies (MDA) by intranasal administration. Seventy-eight 5 to 7-week-old pups were used from 16 litters born to bitches that had been vaccinated with a commercially-available ML CPV-2 vaccine, before mating. Pups were vaccinated initially when they were 5 weeks old. If they failed to seroconvert, they were revaccinated at the age of 7 weeks. The vaccine induced active seroconversion in all the pups with MDA of <= 80, as well as in 66.6% and 37.5% of pups with MDA titers respectively of 160 and 320. None of the pups with MDA titers >= 640 sero-converted after vaccination. Sequence analysis in the ORF2, revealed several amino acid changes in the capsid protein VP2, between the ML CPV-2b virus used in this study and commercially-available type-2 vaccine viruses. The high efficacy of the ML-CPV-2b vaccine in overcoming the MDA obstacle may be accounted for by either the antigenic/biological differences between CPV-2 and the variants 2a/b, or a better induction of active immunization obtainable administering the vaccine by the nasal route.

Immunization of pups with maternal derived antibodies against canine parvovirus, using an intranasally administered modified live canine parvovirus type 2b vaccine [Immunizzazione di cuccioli con anticorpi materni nei confronti del parvovirus del cane con vaccino vivo modificato CPV-2b per via intranasale] / Cavalli, A; Martella, V; Desario, C; Decaro, N; Campolo, M; Corrente, M; Manna, L; Buonavoglia, C. - In: VETERINARIA. - ISSN 0394-3151. - 21(2007), pp. 13-20.

Immunization of pups with maternal derived antibodies against canine parvovirus, using an intranasally administered modified live canine parvovirus type 2b vaccine [Immunizzazione di cuccioli con anticorpi materni nei confronti del parvovirus del cane con vaccino vivo modificato CPV-2b per via intranasale]

CAVALLI, Alessandra;MARTELLA, Vito;DESARIO, COSTANTINA;DECARO, Nicola;CAMPOLO, MARCO;CORRENTE, Marialaura;BUONAVOGLIA, Canio
2007

Abstract

The purpose of this study was to evaluate the ability of a modified live (ML) canine parvovirus (CPV) type 2b vaccine, to elicit active immunization in pups with maternally derived antibodies (MDA) by intranasal administration. Seventy-eight 5 to 7-week-old pups were used from 16 litters born to bitches that had been vaccinated with a commercially-available ML CPV-2 vaccine, before mating. Pups were vaccinated initially when they were 5 weeks old. If they failed to seroconvert, they were revaccinated at the age of 7 weeks. The vaccine induced active seroconversion in all the pups with MDA of <= 80, as well as in 66.6% and 37.5% of pups with MDA titers respectively of 160 and 320. None of the pups with MDA titers >= 640 sero-converted after vaccination. Sequence analysis in the ORF2, revealed several amino acid changes in the capsid protein VP2, between the ML CPV-2b virus used in this study and commercially-available type-2 vaccine viruses. The high efficacy of the ML-CPV-2b vaccine in overcoming the MDA obstacle may be accounted for by either the antigenic/biological differences between CPV-2 and the variants 2a/b, or a better induction of active immunization obtainable administering the vaccine by the nasal route.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11586/116165
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 0
social impact